DOCSLIB.ORG

Peginesatide for Anaemia in Chronic Kidney Disease – First and Second Line

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Peginesatide for Anaemia in Chronic Kidney Disease – First and Second Line Peginesatide for anaemia in chronic kidney disease – first and second line June 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes. The NIHR Horizon Scanning Centre Research Programme is part of the National Institute for Health Research www.nhsc-healthhorizons.org.uk June 2012 Peginesatide for anaemia in chronic kidney disease – first and second line Target group • Symptomatic anaemia: patients on dialysis with chronic kidney disease (CKD) – first and second line. Background Human erythropoietin (EPO) is a protein produced by the kidneys that stimulates the production of red blood cells. Because the kidney is the sole source of EPO synthesis in adults, the reduction in kidney mass that occurs in progressive CKD often causes impairment of EPO production, resulting in anaemia. Technology description Peginesatide (AF-37702) is a synthetic peptide mimetic of EPO that binds directly to the erythropoietin receptor on red blood cell precursors to stimulate red cell formation. Peginesatide is intended as a substitute for currently available erythropoiesis stimulating agents (ESAs) in the treatment of anaemia in CKD dialysis patients. It is administered intravenously (IV) or subcutaneously (SC) at 0.04 mg/kg once monthly. After the initial dose, doses may be titrated to achieve a haemoglobin (Hb) level in the range of 10 to 12g/dL. Peginesatide is also in phase II clinical trials for pure red cell aplasia. Innovation and/or advantages If licensed, peginesatide may offer another treatment option for this patient group. It is administered less frequently than most currently available treatments and can be stored at room temperature for up to three months once dispensed. Developer Takeda Pharmaceuticals Ltd. Availability, launch or marketing dates, and licensing plans Completed phase III clinical trials. NHS or Government Priority Area This topic is relevant to the National Service Framework for Renal Services Part Two: Chronic Kidney Disease, Acute Renal Failure and End of Life Care (2005). Relevant guidance • NICE technology appraisal. Guidance on home compared with hospital haemodialysis for patients with end-stage renal failure. 20021. 2 • NICE clinical guideline. Anaemia management in chronic kidney disease. 2011 . • NICE clinical guideline. Early identification and management of chronic kidney disease in adults in primary and secondary care. 20083. • Kidney Disease: Improving Global Outcomes (KDIGO). Clinical Practice Guideline on Anaemia in CKD in development. Expected 20124. 5 • UK Renal Association. Anaemia of CKD. Clinical practice guidelines. 2010 . 6 • SIGN. Diagnosis and management of chronic kidney disease. 2008 . 2 June 2012 • National Collaborating Centre for Chronic Conditions. Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care. 20087. • National Collaborating Centre for Chronic Conditions. Anaemia management in chronic kidney disease. 20068. • Kidney Disease Outcomes Quality Initiative (KDOQI). National Kidney Foundation clinical practice guidelines and clinical practice recommendations for anaemia in chronic kidney disease in adults. 20069. Clinical need and burden of disease The UK whole population prevalence of stage 3-5 CKD is 4.9%, with an estimated age- standardised prevalence of 8.5% (10.6% in females and 5.8% in males)10. Prevalence of CKD rises dramatically with age and is higher amongst women, and black and minority ethnic groups. Other risk factors for CKD include obesity, diabetes and hypertension1. The prevalence of anaemia in people with CKD depends on the stage of kidney disease, and ranges from 1% in people with moderate decreases in glomerular filtration rate (GFR) to 33% in people with established renal failure11. An estimated 90,000-108,000 of the population in England and Wales have anaemia associated with CKD11. Anaemia is a contributing factor in many of the symptoms associated with reduced kidney function, including fatigue, depression, reduced exercise tolerance and shortness of breath. In addition, anaemia has direct adverse cardiovascular disease (CVD) consequences, such as left ventricular hypertrophy and systolic dysfunction, coronary artery disease, and stroke. As a result, patients with anaemia due to CKD are at increased risk of hospitalisation, increased length of hospital stay, reduced quality of life and 12 increased mortality . Existing comparators and treatments Guidelines suggest that management of anaemia should be considered in people with CKD when their Hb level is≤11g/dL or, if they develop symptoms attributable to anaemia (such as tiredness, shortness of breath, lethargy and palpitations)2. Treatment with ESAs should be offered to patients with anaemia of CKD who are likely to benefit in terms of quality of life and physical function2. Treatment should maintain stable Hb levels between 10 and 12g/dL2. To keep the Hb level within the aspirational range, treatment should be adjusted when Hb levels are within 0.5g/dL of the range’s limits2. The MHRA advise that overcorrection of haemoglobin concentration in patients with CKD may increase the risk of death and serious cardiovascular events13. People receiving ESA maintenance therapy should also be given iron supplements2. Current treatment options include2,14: • Blood transfusion (not indicated for people with anaemia of CKD in whom kidney transplant is a treatment option). • Correction of iron or folate deficiency. • Epoetins - recombinant human erythropoietin. • Darbepoetin (Aranesp) - a hyperglycosylated derivative of epoetin. • Methoxy polyethylene glycol-epoetin beta (Mircera) - a continuous erythropoietin receptor activator. 3 June 2012 Efficacy and safety Trial EMERALD 1, NCT00597753, AFX-01- EMERALD 2, NCT00597584, AFX-01- 12; haemodialysis; peginesatide (IV) or 014; haemodialysis; peginesatide (IV or epoetin alfa; phase III. SC) or epoetin alfa (IV); phase III. Sponsor Affymax. Affymax. Status Complete, unpublished. Complete, unpublished. Source of Abstract15,16, trial registry17, Abstract20,16, trial registry21, information manufacturer18,19. manufacturer18,19. Location USA. USA, EU (inc UK). Design Randomised, active-controlled. Randomised, open-label, active- controlled. Participants n=803; adults; CKD; haemodialysis ≥3 n=823; adults; CKD; haemodialysis ≥3 and schedule months; IV epoetin alfa therapy; Hb months; IV epoetin alfa therapy; Hb values ≥10g/dL and ≤12g/dL. values ≥10g/dL and ≤12g/dL. Randomised to peginesatide, weight- Randomised to peginesatide, weight- based dosing (based on screening epoetin based dosing (based on screening epoetin dose) starting dose 0.04-0.16mg/kg, IV or dose) starting dose 0.04-0.16mg/kg, IV SC every 4 weeks ; or epoetin alpha, or SC every 4 weeks; or epoetin alpha or weight-based dosing, IV or SC 1-3 times beta, weight-based dosing, IV or SC 1-3 weekly. times weekly. Follow-up Up to 6 week screening period, 28 week Up to 6 week screening period, 28 week titration period, 8 week evaluation titration period, 8 week evaluation period); and then ≥16 week long-term period); and then ≥16 week long-term safety and efficacy period. safety and efficacy period. Primary Mean change in Hb. Mean change in Hb. outcome Secondary Red blood cell (RBC) transfusions, Hb RBC transfusions, Hb level 10.0- outcomes level 10.0-12.0g/dL. 12.0g/dL. Key results Peginesatide (n=524) vs epoetin (n=269) Peginesatide (n=542) vs epoetin (n=273) respectively: mean change in Hb (g/dL), - respectively: mean change in Hb (g/dL), - 0.24 vs -0.09 (95% CI -0.29 to -0.01); 0.07 vs -0.17 (95% CI -0.05 to 0.26); RBC transfusions 10.3% vs 8.6%; mean RBC transfusions 7.6% vs 9.9%; mean Hb level maintained at 10-12g/dL during Hb level maintained at 10-12g/dL during evaluation period, 63.0% vs 71.7% evaluation period, 63.5% vs 65.9%; mean (p<0.05); mean Hb during evaluation Hb during evaluation period (g/dL) 11.1 period (g/dL) 11.1 vs 11.3; Hb level vs 11.1; Hb level maintained weeks 1-28 maintained weeks 1-28 (initial titration (initial titration period), 58-68% vs 67- period), 60-69% vs 65-74%; Hb level 78%; Hb level maintained weeks 29-36, maintained weeks 29-36, 63% vs 72%; 64 vs 66%; Hb level maintained weeks Hb level maintained weeks 29-52 29-52 (evaluation and long-term follow (evaluation and long-term follow up up periods), 64-70% vs 65-74%; Hb periods), 67-75% vs 68-75%; Hb levels levels maintained without increasing maintained without increasing RBC RBC transfusion, 8% vs 10%. transfusion, 10% vs 9%. Pooled For peginesatide vs epoetin, respectively: at least one cardiovascular composite results endpointa(CSE); 22.8% vs 24.4%, HR 0.95 (90% CI 0.79 to 1.13). Adverse Peginesatide vs epoetin, respectively: Peginesatide vs epoetin, respectively: effects common AEs: diarrhoea, 20% vs 14%; common AEs: muscle spasm, 20% vs a Composite safety endpoint (CSE) defined as time to first event consisting of death from any cause or a cardiovascular event (myocardial infarction, stroke, or a serious adverse event of congestive heart failure, unstable angina, or arrhythmia). 4 June 2012 cough, 19% vs 20%; dyspnoea, 19% vs 19%; dyspnoea, 18 % vs 18%; nausea, 20%; and nausea,17% vs 19%. 18% vs 20%; and diarrhoea, 17 % vs Serious AEs (SAEs), 58% vs 63%: death, 18%. 11.1% vs 11.2%; stroke, 2.3% vs 4.5 %; SAEs, 49% vs 52%: death, 10.5% vs myocardial infarction, 4.8 % vs 5.9 %; 12.5%; stroke, 2.6% vs 2.9%; myocardial unstable angina, 2.7 % vs 2.6 %; infarction, 4.4% vs 4.8%; unstable congestive heart failure, 11.3 % vs 9.7 %; angina, 1.8% vs 1.8%; congestive heart and arrhythmia, 6.9 % vs 6.7 %. failure, 8.1% vs 8.4%; and arrhythmia, 5.0% vs 6.2%.
Load more

Recommended publications
  • Freedom of Information Act Request – Reference Foi/13/116 New Drugs Added to Formulary
    Freedom of Information Act Request – Reference FoI/13/116 New Drugs Added to Formulary Request details Please will you provide me with numbers of new drugs that your LHB has introduced over the past three years, listing the number of new drugs introduced by year in each of those years? Response 2010 = 41 2011 = 53 2012 = 71 2010 Generic Name 1. adalimumab, etanercept, infliximab, rituximab and abatacept 2. beclometasone and formoterol (Fostair®) 3. bortezomib (Velcade®) in combination with melphalan and prednisone 4. Brinzolamide/timolol (Azarga®) 5. bromocriptine 6. calcium and vitamin D3 (Calceos®) 7. calcium and vitamin D (Adcal D3 Dissolve®) 8. capecitabine 9. Carmellose eye drops (Optive®) 10. Certolizumab pegol 11. Darunavir (Prezista®▼) 12. epoetin alfa (Binocrit®) 13. epoetin theta (Eporatio®) 14. Eslicarbazepine acetate (Zebinix®) 15. Evicel 16. fentanyl buccal tablets (Effentora) 17. fentanyl intranasal spray (Instanyl®) 18. Fesoterodine (Toviaz®) 19. filgrastim (TevaGrastim®) 20. filgrastim (Zarzio®) 21. gefitinib 22. infliximab and adalimumab 23. liraglutide (Victoza®) 24. Loperamide tablets 25. losartan 26. Mepilex® Ag 27. Movicol Paediatric 28. Nebuchamber 29. paclitaxel albumin (Abraxane®) monotherapy 30. pemetrexed 31. Plerixafor (Mozobil®q) 32. pramipexole prolonged release (Mirapexin®) 33. Prontosan® wound irrigation solution and gel 34. quinagolide (Norprolac®) 35. raltegravir (Isentress®) 36. rituximab sildenafil (Revatio®) tablets 2010 Generic Name 37. sodium chloride (7%) Nebusal® 38. somatropin (NutropinAq®) 39. Topotecan 40. Trabectedin 41. Xamiol 2011 Generic Name 1. artemether and lumefantrine (Riamet®) 2. artesunate 3. atazanavir (Reyataz®) co-administered with low dose ritonavir 4. azacitidine 5. aztreonam (Azactam®) 6. bendamustine 7. Bivalirudin 8. Bortezomib 9. Calcium acetate and magnesium carbonate (Osvaren®) 10. darunavir (Prezista®) 11.
    [Show full text]
  • Specialty Drug List 10-22-12 Final
    Iowa Medicaid Specialty Drug List Effective 10/22/2012 “Specialty” drugs include biological drugs, blood-derived products, complex molecules, and select oral, injectable, and infused medications identified by the Department and reimbursed at AWP-17% plus the dispensing fee. Specialty pricing will be applied to both the brand and generic drug products. NOTE: See the PDL at www.iowamedicaidpdl.com for specific PA criteria for the following drugs. BRAND NAME GENERIC NAME AGENTS FOR GAUCHER DISEASE ELELYSO taliglucerase alfa VPRIV velaglucerase alfa ALS RILUTEK riluzole ALCOHOL DEPENDENCE VIVITROL naltrexone AMINOGLYCOSIDES TOBI tobramycin ANTI-ASTHMATICS ALPHA PROTEINASE INHIBITORS ARALAST proteinase inhibitor ARALAST NP proteinase inhibitor PROLASTIN, C proteinase inhibitor ZEMAIRA alpha-1 proteinase inhibitor ANTIASTHMATIC - BETA - ADRENERGICS BRETHINE INJECTION turbutaline sulfate ANTIASTHMATIC - HYDRO-LYTIC ENZYMES KALYDECO ivacaftor ANTIBIOTICS - MISC. CAYSTON aztreonam lysine for inhal soln ANTI-CATAPLECTIC AGENTS XYREM sodium oxybate oral solution ANTICOAGULANTS ARIXTRA fondaparinux sodium FRAGMIN dalteparin sodium INNOHEP tinzaparin sodium LOVENOX enoxaparin sodium ANTICONVULSANTS SABRIL vigabatrin ANTIDOTES FERRIPROX deferiprone ANTIDOTES - CHELATING AGENTS CHEMET succimer EXJADE deferasirox tab for oral susp Page 1 of 10 ANTIEMETIC - TETRAHYDROCANNABINOL (THC) DERIVATIVES MARINOL dronabinol ANTIFUNGALS - ASSORTED AMBISOME amphotericin B Liposome IV for suspension ANCOBON flucytosine CANCIDAS caspofungin acetate for IV solution
    [Show full text]
  • (Epoetin and Darbepoetin) for Treating Cancer Treatment-Induced Anaemia (Including Review of Technology Appraisal No
    HEALTH TECHNOLOGY ASSESSMENT VOLUME 20 ISSUE 13 FEBRUARY 2016 ISSN 1366-5278 The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model Louise Crathorne, Nicola Huxley, Marcela Haasova, Tristan Snowsill, Tracey Jones-Hughes, Martin Hoyle, Simon Briscoe, Helen Coelho, Linda Long, Antonieta Medina-Lara, Ruben Mujica-Mota, Mark Napier and Chris Hyde DOI 10.3310/hta20130 The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model Louise Crathorne,1* Nicola Huxley,1 Marcela Haasova,1 Tristan Snowsill,1 Tracey Jones-Hughes,1 Martin Hoyle,1 Simon Briscoe,1 Helen Coelho,1 Linda Long,1 Antonieta Medina-Lara,2 Ruben Mujica-Mota,1 Mark Napier3 and Chris Hyde1 1Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK 2University of Exeter Medical School, Exeter, UK 3Royal Devon and Exeter Hospital, Exeter, UK *Corresponding author Declared competing interests of authors: none Published February 2016 DOI: 10.3310/hta20130 This report should be referenced as follows: Crathorne L, Huxley N, Haasova M, Snowsill T, Jones-Hughes T, Hoyle M, et al. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model. Health Technol Assess 2016;20(13). Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/ Clinical Medicine.
    [Show full text]
  • Biosimilar Epoetins and Other ``Follow-On
    Biosimilar epoetins and other “follow-on” biologics: Update on the European experiences Wolfgang Jelkmann To cite this version: Wolfgang Jelkmann. Biosimilar epoetins and other “follow-on” biologics: Update on the European experiences. American Journal of Hematology, Wiley, 2010, 85 (10), pp.771. 10.1002/ajh.21805. hal-00552331 HAL Id: hal-00552331 https://hal.archives-ouvertes.fr/hal-00552331 Submitted on 6 Jan 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. American Journal of Hematology Biosimilar epoetins and other “follow-on” biologics: Update on the European experiences For Peer Review Journal: American Journal of Hematology Manuscript ID: AJH-10-0229.R1 Wiley - Manuscript type: Critical Review Date Submitted by the 10-Jun-2010 Author: Complete List of Authors: Jelkmann, Wolfgang; University, Physiology Anemias, Erythropoietin, Hematology- medical, Neutropenia, Keywords: Pharmacology John Wiley & Sons Page 1 of 30 American Journal of Hematology 1 2 3 Table II. Benefits and problems related to the use of biosimilars 4 5 ________________________________________________________________ 6 Benefits Problems 7 ______________________________________________________________________ 8 9 10 Lower pricing than originator medicines Lack of long-term experience 11 (efficacy, safety, immunogenicity?) 12 13 Pressure on innovator companies Product-specific administration routes 14 15 to reduce prices of originator medicines (s.c.
    [Show full text]
  • Specialty Drug Benefit Document
    Louisiana Healthcare Connections Specialty Drug Benefit ouisiana Healthcare Connections provides coverage of a number of specialty drugs. All specialty drugs, such as biopharmaceuticals and injectables, require a prior authorization (PA) to be approved for L payment by Louisiana Healthcare Connections. PA requirements are programmed specific to the drug. Since the list of specialty drugs changes over time due to new drug arrivals and other market conditions, it is important to contact Provider Services at 1-866-595-8133 or check the Louisiana Healthcare Connections website at www.LouisianaHealthConnect.com for updates to this benefit. Requests for specialty drugs can be submitted to Louisiana Healthcare Connections by filling out the Medication Prior Authorization Form that is available on the Louisiana Healthcare Connections website at www.LouisianaHealthConnect.com and faxing the request as instructed on the form. Louisiana Healthcare Connections members can receive the specialty drugs they require at any outpatient pharmacy enrolled in our pharmacy network that can supply specialty drugs. Providers that wish to have drugs distributed by a SPECIALTY PHARMACY should FAX the request to 1-866-399-0929 for review. If a provider wishes to dispense a specialty drug from OFFICE STOCK, the provider should FAX the request to Louisiana Healthcare Connections at 1-877-401-8172 for review. BRAND NAME INGREDIENTS SPECIAL INSTRUCTIONS ACTEMRA TOCILIZUMAB ACTHAR HP CORTICOTROPIN ACTIMMUNE INTERFERON GAMMA-1B ADAGEN PEGADEMASE BOVINE Limited Distribution
    [Show full text]
  • MSM Chapter 1200 3/1/21
    MEDICAID SERVICES MANUAL TRANSMITTAL LETTER February 23, 2021 TO: CUSTODIANS OF MEDICAID SERVICES MANUAL FROM: JESSICA KEMMERER, HIPAA PRIVACY AND CIVIL RIGHTS OFFICER /Jessica Kemmerer/ BACKGROUND AND EXPLANATION The DHCFP is proposing revisions to Medicaid Services Manual (MSM), Chapter 1200 – Prescribed Drugs, Appendix A, to reflect recommendations approved on October 22, 2020, by the Drug Use Review (DUR) Board. The proposed changes include the addition of new prior authorization criteria for Doxepine Topical, the addition of new prior authorization criteria for Zeposia® (ozanimod), addition of new prior authorization for Evenity® (romosozumab-aqqg), Prolia® (denosumab), Forteo® (teriparatide) and Tymlos® (abaloparatide) within a new combined osteoporosis agents section, and addition of new prior authorization criteria for Orilissa® (elagolix) and Oriahnn® (elagolix, estradiol, and norethindrone) within a new Gonadorpin Hormone Receptor (GnRH) Antagonist and Combinations section. Additionally, the DHCFP is proposing revisions to the existing prior authorization criteria for psychotropic medications for children and adolescents, and revision to the existing clinical criteria for Epidiolex® (cannabidiol). Throughout the chapter, grammar, punctuation and capitalization changes were made, duplications removed, acronyms used and standardized, and language reworded for clarity. Renumbering and re- arranging of sections was necessary. These changes are effective March 1, 2021. MATERIAL TRANSMITTED MATERIAL SUPERSEDED MTL N/A MTL N/A MSM Ch 1200 – Prescribed Drugs MSM Ch 1200 – Prescribed Drugs Background and Explanation of Policy Changes, Manual Section Section Title Clarifications and Updates Appendix A Psychotropic Added new policy language criteria on which specific Section N Medications for drug classes may bypass polypharmacy clinical criteria. Children and Adolescents Appendix A Reserved for Future Created a new section titled “Doxepin Topical.” Added Section W Use new prior authorization criteria for doxepin topical.
    [Show full text]
  • OMONTYS® Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION ---------------------DOSAGE FORMS AND STRENGTHS---------------------- These highlights do not include all the information needed to use Dosage Form Strengths OMONTYS® safely and effectively. See full prescribing information for OMONTYS. Single use vials 2 mg/0.5 mL, 3 mg/0.5 mL, (preservative-free) 4 mg/0.5 mL, 5 mg/0.5 mL, and OMONTYS® (peginesatide) Injection, 6 mg/0.5 mL for intravenous or subcutaneous use Single use pre-filled syringes 1 mg/0.5 mL, 2 mg/0.5 mL, Initial U.S. Approval: 2012 (preservative-free) 3 mg/0.5 mL, 4 mg/0.5 mL, 5 mg/0.5 mL, and 6 mg/0.5 mL WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL Multiple use vials 10 mg/mL and 20 mg/2 mL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, (with preservative) THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE -------------------------------CONTRAINDICATIONS------------------------------ See full prescribing information for complete boxed warning. Uncontrolled hypertension (4). Chronic Kidney Disease: In controlled trials, patients experienced greater risks for -----------------------WARNINGS AND PRECAUTIONS------------------------ death, serious adverse cardiovascular reactions, and stroke Increased Mortality, Myocardial Infarction, Stroke, and when administered erythropoiesis-stimulating agents (ESAs) Thromboembolism: Using ESAs to target a hemoglobin level of to target a hemoglobin level of greater than 11 g/dL (5.1). greater than 11 g/dL increases the risk of serious adverse No trial has identified a hemoglobin target level, ESA dose, or cardiovascular reactions and has not been shown to provide dosing strategy that does not increase these risks (5.1). additional benefits (5.1).
    [Show full text]
  • The Curtailment of the European Medicines Agency’S Policy on Access to Documents
    Supplementary Online Content Doshi P. Transparency interrupted: the curtailment of the European Medicines Agency’s policy on access to documents. JAMA Intern Med. Published online August 19, 2013. doi:10.1001/jamainternmed.2013.9989 eAppendix. Table of European Medicines Agency Freedom of Information Requests Snapshot Dated June 4, 2013 This supplementary material has been provided by the authors to give readers additional information about their work. © 2013 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Category of documents Category of documents Affiliation according to Closed Product / subject Pages requested requested social and occupational Received Pending Replied released DOSSIER NON-DOSSIER profile Open Mixed documents Academia/Research Avandia (rosiglitazone) institute 14/12/10 Closed 13/01/11 1,048 Somatropin Studies Other 13/12/10 Closed 14/01/11 0 Tasocitinib Dossier, SA Legal 16/12/10 Closed 18/01/11 0 Duloxetines: Module 5 Ariclaim; Cymbalta; Xeristar; Yentreve Healthcare professional 15/12/10 Closed 16/05/11 13,731 Infanrix HepB Mixed documents Legal 16/12/10 Closed 16/02/11 247 AR, minutes, Dossier, CSR Avonex (interferon beta-1a) Healthcare professional 30/11/10 Closed 04/02/11 18 Travatan (travoprost) AR, PSUR Media 21/12/10 Closed 21/01/11 474 PhVWP H1N1 (pandemic influenza vaccine) EU Institution (EC etc) 20/10/10 Closed 08/02/11 42 Plavix (clopidogrel) CSR Media 04/01/11 Closed 06/09/12 70,291 Referral documents Agreal (veralipride) Patients organisation
    [Show full text]
  • Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (Esas) Still Covered by P
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Erasmus University Digital Repository RESEARCH ARTICLE Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis- Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study Ylenia Ingrasciotta1☯, Francesco Giorgianni1☯, Ilaria Marcianò1☯, Jenny Bolcato2☯, a11111 Roberta Pirolo2☯, Alessandro Chinellato2☯, Valentina Ientile1☯, Domenico Santoro3☯, Armando A. Genazzani4☯, Angela Alibrandi5☯, Andrea Fontana6☯, Achille P. Caputi1,7☯, Gianluca Trifirò1,7,8☯* 1 Unit of Clinical Pharmacology, A.O.U. Policlinico ‘‘G. Martino”, Messina, Italy, 2 Treviso Local Health Unit, Treviso, Italy, 3 Department of Clinical and Experimental Medicine, AOU Policlinico “G. Martino”, University of Messina, Messina, Italy, 4 Department of Pharmaceutical Sciences, ''A. Avogadro'' University, Novara, Italy, 5 Department of Economic Sciences, University of Messina, Messina, Italy, 6 Unit of Biostatistics, OPEN ACCESS IRCCS ‘‘Casa Sollievo della Sofferenza”, San Giovanni Rotondo, FG, Italy, 7 Department of Biomedical and Dental Sciences and Morpho-functional Imaging, University of Messina, Messina, Italy, 8 Department of Citation: Ingrasciotta Y, Giorgianni F, Marcianò I, Medical Informatics, Erasmus Medical Center, Rotterdam, Netherlands Bolcato J, Pirolo R, Chinellato A, et al. (2016) Comparative Effectiveness of Biosimilar, Reference ☯ These authors contributed equally to this work. Product and Other Erythropoiesis-Stimulating Agents * [email protected] (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population- Based Study. PLoS ONE 11(5): e0155805. doi:10.1371/journal.pone.0155805 Abstract Editor: Lorenzo Giovanni Mantovani, FEDERICO II UNIVERSITY OF NAPLES, ITALY Background Received: January 13, 2016 Since 2007 biosimilars of erythropoiesis-stimulating agents (ESAs) are available on the Ital- Accepted: May 4, 2016 ian market.
    [Show full text]
  • Overview of Antibody Drug Delivery
    pharmaceutics Review Overview of Antibody Drug Delivery Sahar Awwad 1,2,* ID and Ukrit Angkawinitwong 1 1 UCL School of Pharmacy, London WC1N 1AX, UK; [email protected] 2 National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London EC1 V9EL, UK * Correspondence: [email protected]; Tel.: +44-207-753-5802 Received: 27 March 2018; Accepted: 29 June 2018; Published: 4 July 2018 Abstract: Monoclonal antibodies (mAbs) are one of the most important classes of therapeutic proteins, which are used to treat a wide number of diseases (e.g., oncology, inflammation and autoimmune diseases). Monoclonal antibody technologies are continuing to evolve to develop medicines with increasingly improved safety profiles, with the identification of new drug targets being one key barrier for new antibody development. There are many opportunities for developing antibody formulations for better patient compliance, cost savings and lifecycle management, e.g., subcutaneous formulations. However, mAb-based medicines also have limitations that impact their clinical use; the most prominent challenges are their short pharmacokinetic properties and stability issues during manufacturing, transport and storage that can lead to aggregation and protein denaturation. The development of long acting protein formulations must maintain protein stability and be able to deliver a large enough dose over a prolonged period. Many strategies are being pursued to improve the formulation and dosage forms of antibodies to improve efficacy and to increase the range of applications for the clinical use of mAbs. Keywords: antibodies; protein; pharmacokinetics; drug delivery; stability 1.
    [Show full text]
  • Pipelinetr Ends
    June 2011 PIPELINE TRxENDS PIPELINE TR ENDS is produced by the x 1-3 Promising New Agents 5 Industry Trends University of Massachusetts Medical School’s 4 Projected Generic Entry 5 Additional Promising Clinical Pharmacy Services division and 4 Investigational Indications New Agents distributed to our clients twice yearly. 4 FDA Updates In This Issue Promising New Promising New Agents Agents Aflibercept Drug Name: Aclidinium bromide Drug Name: Aflibercept BLA submitted Manufacturer: Almirall, Forest Manufacturer: Regeneron, Bayer for wet age- Phase III Indication: COPD BLA Indication: Wet AMD related macular Formulation: Dry powder inhaler Formulation: Intravitreal injection degeneration Dimethyl fumarate Aclidinium bromide, a long-acting, inhaled Aflibercept is under FDA review for the treatment NDA submission anticholinergic bronchodilator, is an antagonist at of the neovascular form of age-related macular planned for the M2 and M3 muscarinic receptors. It is being degeneration (wet AMD). By inhibiting vascular relapsing-remitting multiple sclerosis studied for the treatment of chronic obstructive endothelial and placental growth factors, aflibercept pulmonary disease (COPD). may reduce the abnormal growth of blood vessels Projected Three Phase III, randomized, double-blind trials that damage the retina through blood and fluid leaks. Generic Entry compared aclidinium bromide 200 μg and 400 μg In two double-blind, non-inferiority, Phase III ® Nasacort AQ twice daily to placebo in patients with moderate to studies, VIEW 1 (N=1,217) and VIEW 2 (N=1,240), Levaquin® severe COPD. In each study, the primary endpoint patients with wet AMD were randomized to Uroxatral® Anzemet® was the change in morning trough forced expiratory intravitreal aflibercept 0.5 mg monthly, 2 mg monthly, Zyprexa® volume in one second (FEV1), from baseline to week or 2 mg every two months following three monthly Zyprexa® Zydis® 12.
    [Show full text]
  • Management of Anemia on Hemodialysis
    Chapter 17 Management of Anemia on Hemodialysis Konstantinos Pantelias and Eirini Grapsa Additional information is available at the end of the chapter http://dx.doi.org/10.5772/ 52399 1. Introduction The definition of anemia is controversial. The WHO defines anemia as hemoglobin (Hb)<13 g/dL for men and <12 g/dL for women [1]. The National Kidney Foundation's Kidney Dis‐ ease Outcomes Quality Initiative, which is the criteria used for Medicare reimbursement, de‐ fines anemia in adult men and postmenopausal women as Hb<12 g/dL, or <11 g/dL in a premenopausal woman [2]. Anemia represents a significant problem to deal with in patients with chronic kidney disease (CKD) on hemodialysis (HD). Renal anemia is typically an iso‐ lated normochromic, normocytic anemia with no leukopenia or thrombocytopenia [3]. This is a frequent complication and contributes considerably to reduced quality of life (QoL) [4-6] of patients with CKD. It has also been associated with a number of adverse clinical out‐ comes, increased morbidity and mortality [5, 7-13]. In general, there is a progressive increase in the incidence and severity of anemia with declining renal function. The reported preva‐ lence of anemia by CKD stage varies significantly and depends, to a large extent, on the def‐ inition of anemia and whether study participants selected from the general population, are at a high risk for CKD. Data from the National Health and Nutrition Examination Survey (NHANES) showed that the distribution of Hb levels starts to fall at an estimated glomeru‐ lar filtration rate (eGFR) of less than 75 ml/min per 1.73 m2 in men and 45 ml/min per 1.73 m2 in women [14].
    [Show full text]